Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators.

Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

2.

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators.

Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.

PMID:
19716598
3.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

4.

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.

Kempf DJ, Klein C, Chen HJ, Klein LL, Yeung C, Randolph JT, Lau YY, Chovan LE, Guan Z, Hernandez L, Turner TM, Dandliker PJ, Marsh KC.

Antivir Chem Chemother. 2007;18(3):163-7.

PMID:
17626600
5.

From bacterial genomes to novel antibacterial agents: discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae.

Lerner CG, Hajduk PJ, Wagner R, Wagenaar FL, Woodall C, Gu YG, Searle XB, Florjancic AS, Zhang T, Clark RF, Cooper CS, Mack JC, Yu L, Cai M, Betz SF, Chovan LE, McCall JO, Black-Schaefer CL, Kakavas SJ, Schurdak ME, Comess KM, Walter KA, Edalji R, Dorwin SA, Smith RA, Hebert EJ, Harlan JE, Metzger RE, Merta PJ, Baranowski JL, Coen ML, Thornewell SJ, Shivakumar AG, Saiki AY, Soni N, Bui M, Balli DJ, Sanders WJ, Nilius AM, Holzman TF, Fesik SW, Beutel BA.

Chem Biol Drug Des. 2007 Jun;69(6):395-404.

PMID:
17581233
6.

Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists.

Wang X, Kolasa T, El Kouhen OF, Chovan LE, Black-Shaefer CL, Wagenaar FL, Garton JA, Moreland RB, Honore P, Lau YY, Dandliker PJ, Brioni JD, Stewart AO.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4303-7. Epub 2007 May 16.

PMID:
17532216
7.

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.

Rohde JJ, Pliushchev MA, Sorensen BK, Wodka D, Shuai Q, Wang J, Fung S, Monzon KM, Chiou WJ, Pan L, Deng X, Chovan LE, Ramaiya A, Mullally M, Henry RF, Stolarik DF, Imade HM, Marsh KC, Beno DW, Fey TA, Droz BA, Brune ME, Camp HS, Sham HL, Frevert EU, Jacobson PB, Link JT.

J Med Chem. 2007 Jan 11;50(1):149-64.

PMID:
17201418
8.

Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.

Patel JR, Shuai Q, Dinges J, Winn M, Pliushchev M, Fung S, Monzon K, Chiou W, Wang J, Pan L, Wagaw S, Engstrom K, Kerdesky FA, Longenecker K, Judge R, Qin W, Imade HM, Stolarik D, Beno DW, Brune M, Chovan LE, Sham HL, Jacobson P, Link JT.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):750-5. Epub 2006 Oct 28.

PMID:
17110106
9.

Solid phase extraction as a faster alternative to HPLC: application to MS analysis of metabolic stability samples.

Inman BL, Chovan LE, Dandliker PJ, Lau YY.

J Pharm Sci. 2007 Jun;96(6):1619-24.

PMID:
17094126
10.

Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.

Sorensen B, Winn M, Rohde J, Shuai Q, Wang J, Fung S, Monzon K, Chiou W, Stolarik D, Imade H, Pan L, Deng X, Chovan L, Longenecker K, Judge R, Qin W, Brune M, Camp H, Frevert EU, Jacobson P, Link JT.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):527-32. Epub 2006 Oct 7.

PMID:
17070044
11.

Novel antibacterial class: a series of tetracyclic derivatives.

Hinman MM, Rosenberg TA, Balli D, Black-Schaefer C, Chovan LE, Kalvin D, Merta PJ, Nilius AM, Pratt SD, Soni NB, Wagenaar FL, Weitzberg M, Wagner R, Beutel BA.

J Med Chem. 2006 Aug 10;49(16):4842-56.

PMID:
16884296
12.

Synthesis and antibacterial activity of 5-methoxy- and 5-hydroxy-6-fluoro-1,8-naphthyridone-3-carboxylic acid derivatives.

Matthew Hansen T, Gu YG, Rehm TM, Dandliker PJ, Chovan LE, Bui MH, Nilius AM, Beutel BA.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2716-9.

PMID:
15911248
13.

Automatic mass spectrometry method development for drug discovery: application in metabolic stability assays.

Chovan LE, Black-Schaefer C, Dandliker PJ, Lau YY.

Rapid Commun Mass Spectrom. 2004;18(24):3105-12.

PMID:
15565734
14.

Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants.

Clark RF, Wang S, Ma Z, Weitzberg M, Motter C, Tufano M, Wagner R, Gu YG, Dandliker PJ, Lerner CG, Chovan LE, Cai Y, Black-Schaefer CL, Lynch L, Kalvin D, Nilius AM, Pratt SD, Soni N, Zhang T, Zhang X, Beutel BA.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3299-302.

PMID:
15149694
15.

A strategy for discovery of novel broad-spectrum antibacterials using a high-throughput Streptococcus pneumoniae transcription/translation screen.

Pratt SD, David CA, Black-Schaefer C, Dandliker PJ, Xuei X, Warrior U, Burns DJ, Zhong P, Cao Z, Saiki AY, Lerner CG, Chovan LE, Soni NB, Nilius AM, Wagenaar FL, Merta PJ, Traphagen LM, Beutel BA.

J Biomol Screen. 2004 Feb;9(1):3-11.

PMID:
15006143
16.

Novel antibacterial class.

Dandliker PJ, Pratt SD, Nilius AM, Black-Schaefer C, Ruan X, Towne DL, Clark RF, Englund EE, Wagner R, Weitzberg M, Chovan LE, Hickman RK, Daly MM, Kakavas S, Zhong P, Cao Z, David CA, Xuei X, Lerner CG, Soni NB, Bui M, Shen LL, Cai Y, Merta PJ, Saiki AY, Beutel BA.

Antimicrob Agents Chemother. 2003 Dec;47(12):3831-9.

18.

Solution structure and function of a conserved protein SP14.3 encoded by an essential Streptococcus pneumoniae gene.

Yu L, Gunasekera AH, Mack J, Olejniczak ET, Chovan LE, Ruan X, Towne DL, Lerner CG, Fesik SW.

J Mol Biol. 2001 Aug 17;311(3):593-604.

PMID:
11493012
19.

Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer.

Maine GT, Stricker R, Schuler M, Spesard J, Brojanac S, Iriarte B, Herwig K, Gramins T, Combs B, Wise J, Simmons H, Gram T, Lonze J, Ruzicki D, Byrne B, Clifton JD, Chovan LE, Wachta D, Holas C, Wang D, Wilson T, Tomazic-Allen S, Clements MA, Wright GL Jr, Lazzarotto T, Ripalti A, Landini MP.

J Clin Microbiol. 2000 Apr;38(4):1476-81.

20.

Recombinant antigens to detect Toxoplasma gondii-specific immunoglobulin G and immunoglobulin M in human sera by enzyme immunoassay.

Aubert D, Maine GT, Villena I, Hunt JC, Howard L, Sheu M, Brojanac S, Chovan LE, Nowlan SF, Pinon JM.

J Clin Microbiol. 2000 Mar;38(3):1144-50.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk